- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
Profile
- Financials
Nurix Therapeutics (NRIX)
Company Profile
Quarter (USD) | Feb 25 | Nov 24 | Aug 24 | May 24 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Nov 24 | Nov 23 | Nov 22 | Nov 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 76.82 mm | 76.82 mm | 76.82 mm | 76.82 mm | 76.82 mm | 76.82 mm |
Cash burn (monthly) | 11.36 mm | (no burn) | 20.95 mm | 19.22 mm | 20.36 mm | 15.98 mm |
Cash used (since last report) | 41.88 mm | n/a | 77.25 mm | 70.86 mm | 75.06 mm | 58.90 mm |
Cash remaining | 34.94 mm | n/a | -429.88 k | 5.95 mm | 1.75 mm | 17.92 mm |
Runway (months of cash) | 3.1 | n/a | -0.0 | 0.3 | 0.1 | 1.1 |
13F holders | Current |
---|---|
Total holders | 177 |
Opened positions | 38 |
Closed positions | 34 |
Increased positions | 66 |
Reduced positions | 47 |
13F shares | Current |
---|---|
Total value | 1.41 tn |
Total shares | 82.65 mm |
Total puts | 42.40 k |
Total calls | 317.80 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
FMR | 10.63 mm | $200.35 bn |
BlackRock | 7.68 mm | $144.61 bn |
Vanguard | 4.35 mm | $81.86 bn |
Redmile | 4.19 mm | $78.99 bn |
Baker Bros. Advisors | 3.88 mm | $73.14 bn |
Wellington Management | 3.59 mm | $67.57 bn |
T. Rowe Price | 3.01 mm | $56.66 mm |
Commodore Capital | 3.00 mm | $56.52 bn |
Deep Track Capital | 3.00 mm | $56.52 bn |
STT State Street | 2.80 mm | $52.81 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 May 25 | Reinsdorf Judith A | Director Stock Option Common Stock | Grant | Acquire A | No | No | 9.51 | 25,000 | 237.75 k | 25,000 |
19 May 25 | Lori Anne Kunkel | Director Stock Option Common Stock | Grant | Acquire A | No | No | 9.51 | 25,000 | 237.75 k | 25,000 |
19 May 25 | Gregory Julia P | Director Stock Option Common Stock | Grant | Acquire A | No | No | 9.51 | 25,000 | 237.75 k | 25,000 |
19 May 25 | Edward C Saltzman | Director Stock Option Common Stock | Grant | Acquire A | No | No | 9.51 | 25,000 | 237.75 k | 25,000 |
19 May 25 | Lacey David L. | Director Stock Option Common Stock | Grant | Acquire A | No | No | 9.51 | 25,000 | 237.75 k | 25,000 |